These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 27875974)

  • 1. Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy.
    Wilkerson A; Kim J; Huang AY; Zhang M
    Curr Top Med Chem; 2017; 17(16):1843-1857. PubMed ID: 27875974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms overseeing myeloid-derived suppressor cell production in neoplastic disease.
    Netherby CS; Abrams SI
    Cancer Immunol Immunother; 2017 Aug; 66(8):989-996. PubMed ID: 28224211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer.
    Albeituni SH; Ding C; Yan J
    Cancer J; 2013; 19(6):490-501. PubMed ID: 24270348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloid-derived suppressor cells: The green light for myeloma immune escape.
    Malek E; de Lima M; Letterio JJ; Kim BG; Finke JH; Driscoll JJ; Giralt SA
    Blood Rev; 2016 Sep; 30(5):341-8. PubMed ID: 27132116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid-Derived Suppressor Cells and Therapeutic Strategies in Cancer.
    Katoh H; Watanabe M
    Mediators Inflamm; 2015; 2015():159269. PubMed ID: 26078490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IRF7 regulates the development of granulocytic myeloid-derived suppressor cells through S100A9 transrepression in cancer.
    Yang Q; Li X; Chen H; Cao Y; Xiao Q; He Y; Wei J; Zhou J
    Oncogene; 2017 May; 36(21):2969-2980. PubMed ID: 28092673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid-derived suppressor cells-a new therapeutic target to overcome resistance to cancer immunotherapy.
    Chesney JA; Mitchell RA; Yaddanapudi K
    J Leukoc Biol; 2017 Sep; 102(3):727-740. PubMed ID: 28546500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.
    Groth C; Hu X; Weber R; Fleming V; Altevogt P; Utikal J; Umansky V
    Br J Cancer; 2019 Jan; 120(1):16-25. PubMed ID: 30413826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycolysis regulates the expansion of myeloid-derived suppressor cells in tumor-bearing hosts through prevention of ROS-mediated apoptosis.
    Jian SL; Chen WW; Su YC; Su YW; Chuang TH; Hsu SC; Huang LR
    Cell Death Dis; 2017 May; 8(5):e2779. PubMed ID: 28492541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of T cells by myeloid-derived suppressor cells in cancer.
    Chen J; Ye Y; Liu P; Yu W; Wei F; Li H; Yu J
    Hum Immunol; 2017 Feb; 78(2):113-119. PubMed ID: 27939507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloid-derived suppressor cells as effectors of immune suppression in cancer.
    Pyzer AR; Cole L; Rosenblatt J; Avigan DE
    Int J Cancer; 2016 Nov; 139(9):1915-26. PubMed ID: 27299510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies.
    Shou D; Wen L; Song Z; Yin J; Sun Q; Gong W
    Oncotarget; 2016 Sep; 7(39):64505-64511. PubMed ID: 27542274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Myeloid-Derived Suppressor Cells in Cancer.
    Anani W; Shurin MR
    Adv Exp Med Biol; 2017; 1036():105-128. PubMed ID: 29275468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.
    Dubinski D; Wölfer J; Hasselblatt M; Schneider-Hohendorf T; Bogdahn U; Stummer W; Wiendl H; Grauer OM
    Neuro Oncol; 2016 Jun; 18(6):807-18. PubMed ID: 26578623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.
    Parker KH; Beury DW; Ostrand-Rosenberg S
    Adv Cancer Res; 2015; 128():95-139. PubMed ID: 26216631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Current Knowledge and Future Perspectives.
    Ibáñez-Vea M; Zuazo M; Gato M; Arasanz H; Fernández-Hinojal G; Escors D; Kochan G
    Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):113-123. PubMed ID: 29032490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional Diversity of Myeloid-Derived Suppressor Cells: The Multitasking Hydra of Cancer.
    Jayakumar A; Bothwell ALM
    J Immunol; 2019 Sep; 203(5):1095-1103. PubMed ID: 31427398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the origin of myeloid-derived suppressor cells.
    Millrud CR; Bergenfelz C; Leandersson K
    Oncotarget; 2017 Jan; 8(2):3649-3665. PubMed ID: 27690299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tracking the fate of adoptively transferred myeloid-derived suppressor cells in the primary breast tumor microenvironment.
    Sceneay J; Griessinger CM; Hoffmann SHL; Wen SW; Wong CSF; Krumeich S; Kneilling M; Pichler BJ; Möller A
    PLoS One; 2018; 13(4):e0196040. PubMed ID: 29677215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The immunobiology of myeloid-derived suppressor cells in cancer.
    Motallebnezhad M; Jadidi-Niaragh F; Qamsari ES; Bagheri S; Gharibi T; Yousefi M
    Tumour Biol; 2016 Feb; 37(2):1387-406. PubMed ID: 26611648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.